US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sanofi SA

52.32

-1.2200-2.28%

Post-market: 52.420.1000+0.19%19:20 EDT

Volume:5.49M

Turnover:288.52M

Market Cap:128.08B

PE:22.76

High:52.92

Open:52.86

Low:52.23

Close:53.54

Loading ...

Overview Company News Filings

Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus

Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus

Q4 2024 Cytokinetics Inc Earnings Call

Thomson Reuters StreetEvents

Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ...

Novavax Inc (NVAX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial ...

Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds

Q4 2024 Vir Biotechnology Inc Earnings Call

Thomson Reuters StreetEvents

Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value

Novavax reports large quarterly revenue declines, rethinks its strategic direction

Novavax shares up on fourth quarter earnings beat

Pfizer Hires Top FDA Official Just Weeks After She Leaves Agency -- Barrons.com

Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease

The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis

Teva, Sanofi present new results from RELIEVE UCCD Phase 2b study

Sanofi (SNY): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More

Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies’ Board of Directors at 2025 Annual Meeting

SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag

Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Bullous Pemphigoid

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SNY/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SNY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNY\",,,,,undefined,":{"symbol":"SNY","market":"US","secType":"STK","nameCN":"Sanofi SA","latestPrice":52.32,"timestamp":1745611200000,"preClose":53.54,"halted":0,"volume":5488691,"hourTrading":{"tag":"盘后","latestPrice":52.42,"preClose":52.32,"latestTime":"19:20 EDT","volume":17285,"amount":904819.14,"timestamp":1745623210076},"delay":0,"floatShares":2205948514,"shares":2448069980,"eps":2.298867,"marketStatus":"Market Closed","change":-1.22,"latestTime":"04-25 16:00:00 EDT","open":52.86,"high":52.92,"low":52.225,"amount":288515951.42123,"amplitude":0.012981,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.298867,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":1,"adrRate":0.5,"listingDate":1025496000000,"exchange":"NASDAQ","adjPreClose":53.54,"dividendRate":0.042633,"preHourTrading":{"tag":"盘前","latestPrice":52.9,"preClose":53.54,"latestTime":"09:28 EDT","volume":286184,"amount":15125377.593672,"timestamp":1745587680217},"postHourTrading":{"tag":"盘后","latestPrice":52.42,"preClose":52.32,"latestTime":"19:20 EDT","volume":17285,"amount":904819.14,"timestamp":1745623210076},"volumeRatio":1.6082988738407291,"impliedVol":0.2786,"impliedVolPercentile":0.516},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNY\",,,,,undefined,":{"symbol":"SNY","floatShares":2205948514,"roa":"4.28%","roe":"7.30%","lyrEps":2.29994,"volumeRatio":1.6082988738407291,"shares":2448069980,"dividePrice":2.230568,"high":52.92,"amplitude":0.012981,"preClose":53.54,"low":52.225,"week52Low":45.8,"pbRate":"1.45","psRate":"2.49","week52High":60.115,"institutionHeld":0.0837,"latestPrice":52.32,"eps":2.298867,"divideRate":0.042633,"volume":5488691,"delay":0,"ttmEps":2.298867,"open":52.86,"prevYearClose":48.23,"prevWeekClose":50.9,"prevMonthClose":55.46,"prevQuarterClose":55.46,"fiveDayClose":50.9,"twentyDayClose":54.91,"sixtyDayClose":52.15},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SNY\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516330551","title":"Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2516330551","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516330551?lang=en_us&edition=fundamental","pubTime":"2025-03-01 02:14","pubTimestamp":1740766440,"startTime":"0","endTime":"0","summary":"Cytokinetics, Incorporated CYTK reported a net loss of $1.26 per share in the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.22. In the year-ago quarter, the company reported a net loss of $1.38 per share.Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Revenues totaled $16.9 million, which missed the Zacks Consensus Estimate of $20 million. The top line was up from $1.7 million recorded in the year-ago quarter.Total revenues in fourth-quarter and full-year 2024 benefited from a $15.0 million upfront milestone payment from Corxel Pharmaceuticals.Since the company does not have any approved product in its portfolio yet, it does not generate drug sales.Cytokinet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cytokinetics-q4-loss-wider-expected-181400233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4007","SNY","BK4588","BK4531","CYTK","BAYRY","HCM","IE00BFXG1179.USD","BK4505","BK4139"],"gpt_icon":0},{"id":"2516130552","title":"Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2516130552","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516130552?lang=en_us&edition=fundamental","pubTime":"2025-03-01 02:12","pubTimestamp":1740766320,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. KYMR reported a fourth-quarter 2024 loss of 88 cents per share, wider than the Zacks Consensus Estimate of a loss of 76 cents. In the year-ago quarter, Kymera reported a loss of 25 cents per share.The year-over-year deterioration was due to lower collaboration revenues and higher operating expenses.Collaboration revenues totaled $7.4 million, which missed the Zacks Consensus Estimate of $13 million.In the year-ago quarter, Kymera earned collaboration revenues of $47.9 million due to the recognition of milestone payments related to the advancement of KT-474 into phase II testing under its collaboration with pharma bigwig Sanofi SNY.Shares of KYMR have lost 30.1% year to date compared with the industry’s decline of 8%.In October, Kymera initiated the phase I study on KT-621 in healthy volunteers. KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6.Kymera intends to advance KT-295, an investigational, first-in-class, once daily, oral ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kymeras-q4-loss-wider-expected-181200761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","IE0002270589.USD","LU0889565916.HKD","BK4568","LU1571399168.USD","LU1839511570.USD","LU2087621335.USD","IE00BSNM7G36.USD","BK4588","IE00B19Z3581.USD","IE00BKVL7J92.USD","BMRN","BK4139","BK4583","LU0058720904.USD","LU1066053197.SGD","BK4578","LU0320765992.SGD","BK4007","IE00BFXG1179.USD","LU0234570918.USD","LU2468319806.SGD","BK4532","GILD","BK4550","KYMR","LU1430594728.SGD","IE00BZ1G4Q59.USD","LU1585245621.USD","LU0109394709.USD","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","LU1066051498.USD","LU2089984988.USD","LU0289739699.SGD","SNY","BK4566","IE00B3T34201.USD"],"gpt_icon":0},{"id":"2516707376","title":"Q4 2024 Cytokinetics Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2516707376","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516707376?lang=en_us&edition=fundamental","pubTime":"2025-03-01 00:00","pubTimestamp":1740758423,"startTime":"0","endTime":"0","summary":"Robert Blum; President, Chief Executive Officer, Director; Cytokinetics Inc. Andrew Callos; Executive Vice President, Chief Commercial Officer; Cytokinetics Inc. Isaac Ciechanover; Executive Vice President, Corporate Development and Chief Business Officer; Cytokinetics Inc. Stuart Kupfer; Senior Vice President, Chief Medical Officer; Cytokinetics Inc. Good afternoon, and welcome to Cytokinetics' fourth-quarter 2024 conference call. At this time, I would like to inform you that this call is being recorded.  I will now turn the call over to Diane Weiser, Cytokinetics' Senior Vice President of Corporate Affairs. Please go ahead.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-cytokinetics-inc-earnings-160023099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNY","CYTK"],"gpt_icon":0},{"id":"2514134303","title":"Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2514134303","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514134303?lang=en_us&edition=fundamental","pubTime":"2025-02-28 15:15","pubTimestamp":1740726959,"startTime":"0","endTime":"0","summary":"R&D Expenses: $71.8 million, including $6.8 million in non-cash stock-based compensation.Adjusted Cash R&D Spend: $65 million, a 23% increase from the previous quarter.G&A Expenses: $16.3 million, including $7 million in non-cash stock-based compensation.Adjusted Cash G&A Spend: $9.3 million, a 13% increase from the previous quarter.Cash Balance: $851 million, providing a runway into mid-2027.GuruFocus has detected 3 Warning Signs with KYMR.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Kymera Therapeutics Inc  is on track to report significant clinical data in 2025, including Phase I data for KT-621 and advancing KT-295 into the clinic.Kymera Therapeutics Inc  has high R&D expenses, with a 23% sequential increase in adjusted cash R&D spend from the third quarter.A: Jared Gollob, Chief Medical Officer, explained that prior dupilumab trials showed clear impacts on Th2 biomarkers and clinical endpoints like EASI and pruritus NRS within","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kymera-therapeutics-inc-kymr-q4-071559722.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNY","KYMR"],"gpt_icon":0},{"id":"2514131763","title":"Novavax Inc (NVAX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2514131763","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514131763?lang=en_us&edition=fundamental","pubTime":"2025-02-28 15:11","pubTimestamp":1740726682,"startTime":"0","endTime":"0","summary":"Total Revenue: $682 million for the full year 2024.Product Sales: $190 million, primarily from US and European markets.Licensing, Royalties, and Other Revenue: $492 million for 2024.4th Quarter Revenue: $88 million, with $50 million from product sales.R&D and SG&A Expenses: Reduced by 40% in 2024 compared to 2023.4th Quarter R&D and SG&A Expenses: $183 million, a 43% reduction from the same period in 2023.Cash and Receivables: Over $1 billion at the end of 2024.Sale of Czech Republic Facility: $200 million, contributing to a $52 million gain in Q4.Current Liabilities Reduction: Decreased by $481 million in 2024.2025 Revenue Framework: Expected adjusted licensing, royalties, and other revenue between $300 million and $350 million.2025 R&D and SG&A Expense Target: Between $475 million and $525 million, with a focus on R&D.Milestone Payments: Potential $225 million from COVID-19 BLA approval and market authorization transfers.GuruFocus has detected 4 Warning Signs with NVAX.Novavax Inc  a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novavax-inc-nvax-q4-2024-071122123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNY","NVAX"],"gpt_icon":1},{"id":"2514233439","title":"Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds","url":"https://stock-news.laohu8.com/highlight/detail?id=2514233439","media":"Blockhead","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514233439?lang=en_us&edition=fundamental","pubTime":"2025-02-28 03:30","pubTimestamp":1740684637,"startTime":"0","endTime":"0","summary":"Moderna stock toppled Thursday on reports the Trump administration is considering pulling bird flu vaccine funding.","market":"us","thumbnail":"https://www.investors.com/wp-content/uploads/2020/11/Stock-moderna-02-shutt-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2020/11/Stock-moderna-02-shutt-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/moderna-stock-rfk-jr-bird-flu-vaccine-funds/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["LU1829250122.USD","LU0306806265.USD","GSK","SNY","LU1023059063.AUD","LU0985481810.HKD","LU0289739699.SGD","LU1883839398.USD","SG9999003800.SGD","LU1057294990.SGD","BK4533","IE00BBT3K403.USD","BK7095","IE00B19Z3581.USD","SG9999002232.USD","LU0122379950.USD","BK4581","BK4599","LU0456855351.SGD","LU0225771236.USD","LU0058720904.USD","LU0170899867.USD","IE00BLSP4452.SGD","SG9999001176.SGD","BK4550","GSK.UK","BK4534","BK4139","LU0321505439.SGD","LU0306807586.USD","SG9999013999.USD","LU1066053197.SGD","LU0868494617.USD","MRNA","BK4007","IE00BLSP4239.USD","IE00B19Z3B42.SGD","LU1894683264.USD","IE00BFXG1179.USD","LU0321505868.SGD","LU1894683348.USD","BK4592","IE000M9KFDE8.USD","PFE.AU","BK4501","SGXZ57979304.SGD","SG9999001176.USD","BK4585","LU0225284248.USD"],"gpt_icon":1},{"id":"2514445336","title":"Q4 2024 Vir Biotechnology Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2514445336","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514445336?lang=en_us&edition=fundamental","pubTime":"2025-02-28 02:30","pubTimestamp":1740681012,"startTime":"0","endTime":"0","summary":"Richard Lepke; Senior Director of Investor Relations; Vir Biotechnology Inc. Marianne De Backer; Chief Executive Officer, Director; Vir Biotechnology Inc. Mark Eisner; Executive Vice President & Chief Medical Officer; Vir Biotechnology Inc. Jason O'Byrne; Executive Vice President & Chief Financial Officer; Vir Biotechnology Inc. Mika Derynck; Executive Vice President, Therapeutic Area Head Oncology; Vir Biotechnology Inc. Paul Choi; Analyst; Goldman Sachs & Company, Inc.Thank you, Rich, and good afternoon, everyone. Thank you for joining us for our fourth-quarter and full-year 2024 earnings call. I'm truly excited to share our progress with you today. 2024 was nothing short of transformative for Vir Biotechnology. As I reflect on the past year, I'm incredibly proud of what we've accomplished. We've made significant strides in our oncology and infectious disease programs, positioning Vir Bio at the forefront of innovative therapies in these areas of critical unmet medical need. Our stra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-vir-biotechnology-inc-183012964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VIR","SNY","ALNY"],"gpt_icon":0},{"id":"2514138209","title":"Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2514138209","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514138209?lang=en_us&edition=fundamental","pubTime":"2025-02-28 00:24","pubTimestamp":1740673450,"startTime":"0","endTime":"0","summary":"Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships and expects up to $350 million in 2025 revenue.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/25/02/44013531/novavax-reports-smaller-q4-loss-shifts-focus-from-commercializing-covid-19-vaccine-to-maximize-value","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4585","BK4568","SNY","BK4007","IE00BFXG1179.USD","BK4588","BNTX","BK4139","NVAX"],"gpt_icon":0},{"id":"2514385161","title":"Novavax reports large quarterly revenue declines, rethinks its strategic direction","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385161","media":"Yahoo Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514385161?lang=en_us&edition=fundamental","pubTime":"2025-02-27 22:46","pubTimestamp":1740667615,"startTime":"0","endTime":"0","summary":"Novavax  reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a vaccine maker.The COVID-19 vaccine company, based in Maryland, said during its earnings report that it would move from developing products to instead partnering with larger pharmaceutical companies and licensing its drug technology.Novavax reported $88 million in revenues in the fourth quarter, compared to $291 million the year prior, and $682 million for the full year 2024, compared to $984 million the previous year. The sharp decline reflected slumping sales of its COVID-19 vaccine — similar to other vaccine makers. Sales figures also reflected revenues of $200 million from the sale of a manufacturing facility in the Czech Republic to Novo Nordisk .Wall Street expected $84 million in revenues for the quarter and a loss per share of $0.75 for the quarter. The company reported a loss of $0.51 for the quarter, beating estimates, and loss of $1.23 per share for the full y","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novavax-reports-large-quarterly-revenue-declines-rethinks-its-strategic-direction-144655966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PFE","SNY","NVO","NVAX"],"gpt_icon":1},{"id":"2514438388","title":"Novavax shares up on fourth quarter earnings beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2514438388","media":"Investing.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514438388?lang=en_us&edition=fundamental","pubTime":"2025-02-27 22:25","pubTimestamp":1740666315,"startTime":"0","endTime":"0","summary":"Investing.com --Shares of Novavax  rose about 1.75% in premarket trading after reporting a smaller-than-expected quarterly loss but it missed revenue estimates. The company is transitioning away from direct commercialization of its COVID-19 vaccine.The vaccine maker posted a fourth-quarter loss per share of $0.51, beating analysts’ expectations of a 60-cent loss on each share. Revenue came in at $88.31 million, below the consensus estimate of $102.74 million.Novavax said it was transitioning away from commercial responsibilityof its COVID-19 vaccine, Nuvaxovid, giving it to Sanofi  starting with the 2025-2026 season. The company also secured a $50 million milestone payment under its Sanofi agreement and completed the $200 million sale of its Czech Republic manufacturing facility to Novo Nordisk , a move expected to reduce annual costs by about $80 million.The company ended 2024 with over $1 billion in cash and accounts receivables and provided 2025 financial guidance. CEO John C. Jacob","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novavax-shares-fourth-quarter-earnings-142515939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNY","NVAX"],"gpt_icon":0},{"id":"2514295777","title":"Pfizer Hires Top FDA Official Just Weeks After She Leaves Agency -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2514295777","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514295777?lang=en_us&edition=fundamental","pubTime":"2025-02-25 03:04","pubTimestamp":1740423840,"startTime":"0","endTime":"0","summary":"Pfizer said Monday it hired Dr. Patrizia Cavazzoni, who stepped down from one of the Food and Drug Administration's top jobs just over a month ago, to replace its chief medical officer.The announcement comes days after the new secretary of the U.S. Department of Health and Human Services, Robert F. Kennedy Jr., said in an address to his staff that he would \"shut the revolving door to reestablish public trust\" in the department.Until Jan. 18, Cavazzoni was director of the Center for Drug Evaluation and Research, the division within the FDA that regulates most human medicines and is responsible for the approval of most new drugs.As CDER director since 2021, Cavazzoni was one of the top FDA officials and perhaps the federal regulator with the most influence over the pharmaceutical industry.Cavazzoni won't be the only former top FDA official at Pfizer: Dr. Scott Gottlieb, who was FDA commissioner from 2017 through 2019, is a member of the board of directors.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000M9KFDE8.USD","LU0234572021.USD","IE00BJT1NW94.SGD","LU2491050154.USD","LU0456855351.SGD","LU2211815571.USD","LU1989771016.USD","LU1127390331.HKD","IE0009355771.USD","BK4532","LU0058720904.USD","LU1988902786.USD","IE00BLSP4239.USD","IE0002270589.USD","LU2265009873.SGD","SNY","IE0002141913.USD","SG9999014906.USD","LU1720051017.SGD","SG9999017495.SGD","LU0198837287.USD","LU2602419157.SGD","LU0061475181.USD","PFE","LU0417517546.SGD","SG9999015952.SGD","LU1069344957.HKD","LU1267930730.SGD","LU1894683264.USD","LU0122379950.USD","LU0114720955.EUR","LU0306806265.USD","LU1868837300.USD","IE00B2B36J28.USD","LU0820561909.HKD","SGXZ51526630.SGD","LU2237438978.USD","LU0256863902.USD","LU0106261372.USD","LU1623119135.USD","LU0097036916.USD","LU2112291526.USD","LU2237443978.SGD","BIIB","BK4585","LU2106854487.HKD","LU0354030438.USD","LU0820561818.USD","LU2468319806.SGD"],"gpt_icon":1},{"id":"2513721338","title":"Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2513721338","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513721338?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:22","pubTimestamp":1740403320,"startTime":"0","endTime":"0","summary":"On Saturday, Teva Pharmaceuticals Industries Ltd.  and Sanofi SA  presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug  for moderate-to-severe ulcerative colitis  and Crohn’s disease , the two most common forms of inflammatory bowel disease .These results were shared at the Congress of the European Crohn’s and Colitis Organisation.Also Read: Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As ‘Top Pick For 2025’。In the UC cohort of the RELIEVE UCCD study, 36%  and 48%  of patients treated with duvakitug achieved the primary endpoint of clinical remission  at week 14 compared to 20% treated with placebo.Higher clinical remission rates were observed for both doses of duvakitug versus placebo in both advanced therapy -experienced and AT-nave subgroups of patients.AT-experienced: 29%  and 36% , with placebo-adjusted rates of 22%  and 29% .AT-nave: 39%  and 53% , with placebo-adjusted rates of 12%  a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sanofi-teva-unveil-detailed-data-132200188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4559","IE00BFXG1179.USD","SNY","SNYNF","CD","BK4584","BK4557","BK4585","IBD","BK4116","BK4566","TEVA","BK4007","BK4596","BK4588"],"gpt_icon":0},{"id":"2513744949","title":"The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis","url":"https://stock-news.laohu8.com/highlight/detail?id=2513744949","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513744949?lang=en_us&edition=fundamental","pubTime":"2025-02-24 17:46","pubTimestamp":1740390360,"startTime":"0","endTime":"0","summary":"Chicago, IL – February 24, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Merck MRK, Sanofi SNY, Regeneron REGN and Ionis Pharmaceuticals IONS.Pharma Stock Roundup: EU Nod to Key Drug and Q4 Earnings Results. This week, the European Commission granted approval to Merck’s novel HIF-2α inhibitor, Welireg, for two indications. The FDA granted priority review to a supplemental biologics license application  seeking approval of Sanofi and Regeneron’s blockbuster drug, Dupixent, for a new indication, bullous pemphigoid. Ionis Pharmaceuticals announced its fourth-quarter and full-year 2024 results.Here's a recap of the week’s most important stories.EU Approval to Merck’s Welireg for Two Indications. Dupixent is currently approved in several countries, including the United States and EU, for six ty","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-analyst-blog-highlights-merck-094600312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0985320562.USD","IE00BBT3K403.USD","LU1929549753.HKD","LU1430594728.SGD","MRK","LU1941712264.USD","LU1989772840.SGD","LU0889565916.HKD","SG9999014559.SGD","LU1093756168.USD","LU1057294990.SGD","LU1116320901.HKD","LU2237438978.USD","SNY","LU1066051225.USD","LU1162221912.USD","LU2112291526.USD","LU1989771016.USD","LU2089984988.USD","LU0265550359.USD","LU1699723380.USD","LU0058720904.USD","LU2361044949.HKD","LU0006306889.USD","LU2362541513.USD","BK4007","LU0070302665.USD","LU0965509010.AUD","IONS","LU2023250504.SGD","LU1934455863.HKD","LU2468319806.SGD","LU0234572021.USD","LU0320765646.SGD","SG9999015358.SGD","LU0265550946.USD","SG9999001440.SGD","IE00BFTCPJ56.SGD","SG9999014575.USD","LU1585245621.USD","SGXZ57979304.SGD","SNYNF","IE0002141913.USD","LU1941712348.USD","REGN","LU1066051498.USD","LU0320765489.SGD","LU1989772923.USD","LU0106261372.USD","LU1934455277.USD"],"gpt_icon":0},{"id":"2513589407","title":"Teva, Sanofi present new results from RELIEVE UCCD Phase 2b study","url":"https://stock-news.laohu8.com/highlight/detail?id=2513589407","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513589407?lang=en_us&edition=fundamental","pubTime":"2025-02-23 21:40","pubTimestamp":1740318033,"startTime":"0","endTime":"0","summary":"Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 mon...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-sanofi-present-new-results-from-relieve-uccd-phase-2b-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-sanofi-present-new-results-from-relieve-uccd-phase-2b-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNY","BK4566","BK4007","SNYNF","TEVA","IE00BFXG1179.USD","BK4557","BK4559","BK4584","BK4585","BK4596","BK4588"],"gpt_icon":0},{"id":"2513784693","title":"Sanofi (SNY): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2513784693","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513784693?lang=en_us&edition=fundamental","pubTime":"2025-02-23 12:04","pubTimestamp":1740283498,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts.In this article, we are going to take a look at where Sanofi  stands against the other pharmaceutical stocks.The Evolving Landscape of Healthcare and Biopharma Innovation. The possibility for additional participants to enter the field is growing along with the possible applications of GLP-1s. For example, the Swiss business Roche entered the weight-loss drug sweepstakes in 2023 when it paid up to $3.1 billion to acquire California-based Carmot Therapeutics. The corporation wants to \"fast-track\" its anti-obesity medicines to regain faith in its pipeline and take a share of the weight-loss market.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sanofi-sny-among-cheap-pharmaceutical-040458381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USAW.SI","IE00BMPRXR70.SGD","IE00BFXG1179.USD","CAGR","QLD","TQQQ","BK4543","IE00BMPRXN33.USD","IE00BMPRXQ63.HKD","BK4141","BK4159","NVIW.SI","PSQ","SNY","TSYW.SI","BK4609","LU0348723411.USD","QID","BK4585","USJW.SI","NQmain","BK4007","SQQQ","BK4588","MNQmain",".IXIC"],"gpt_icon":1},{"id":"2513141222","title":"Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2513141222","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513141222?lang=en_us&edition=fundamental","pubTime":"2025-02-22 15:20","pubTimestamp":1740208800,"startTime":"0","endTime":"0","summary":"Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ETNew detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/22/3030763/0/en/Teva-and-Sanofi-Present-New-Positive-Phase-2b-Study-Results-at-ECCO-2025-Reinforcing-Best-in-Class-Potential-of-Duvakitug-Anti-TL1A-in-Ulcerative-Colitis-and-Crohn-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CD","BK4585","SNY","SNYNF","IE00BFXG1179.USD","IBD","BK4588","BK4116"],"gpt_icon":0},{"id":"2513291467","title":"Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2513291467","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513291467?lang=en_us&edition=fundamental","pubTime":"2025-02-21 21:41","pubTimestamp":1740145260,"startTime":"0","endTime":"0","summary":"This week, the European Commission granted approval to Merck’s MRK novel HIF-2α inhibitor, Welireg, for two indications. The FDA granted priority review to a supplemental biologics license application  seeking approval of Sanofi SNY and Regeneron’s REGN blockbuster drug, Dupixent, for a new indication, bullous pemphigoid. Ionis Pharmaceuticals IONS announced its fourth-quarter and full-year 2024 results.Here's a recap of the week’s most important stories.IONS reported better-than-expected top and bottom-line numbers for the fourth quarter. Its loss of 66 cents per share was narrower than the Zacks Consensus Estimate of a loss of $1.12 per share. Total revenues of $227 million beat the Zacks Consensus Estimate of $137.5 million. However, revenues declined 30.2% year over year. Commercial revenues were $86 million in the fourth quarter, up 8.9% year over year. R&D revenues declined 42.7% year over year to $141 million.EU Approval to Merck’s Welireg for Two Indications. The NYSE ARCA Phar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-eu-nod-134100358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4533","LU2112291526.USD","IE00B2B36J28.USD","LU0823416689.USD","BK4156","SG9999014559.SGD","SG9999001440.SGD","BK4588","SG9999001176.USD","IONS","LU0985320562.USD","LU1934455863.HKD","LU0882574055.USD","LU0965509283.SGD","SG9999014575.USD","BK4516","SGXZ57979304.SGD","LU2237438978.USD","LU2361045086.USD","IE00BBT3K403.USD","LU0965509101.SGD","LU1061106388.HKD","SG9999015358.SGD","LU0070302665.USD","SG9999013999.USD","LU0053666078.USD","LU1929549753.HKD","SG9999002232.USD","LU1430594728.SGD","REGN","LU2361044949.HKD","SG9999014542.SGD","LU0203345920.USD","LU1585245621.USD","MRK","LU1934455277.USD","LU1066051498.USD","LU1066051225.USD","LU0266013472.USD","LU1162221912.USD","LU1934455194.USD","LU2023250843.SGD","SNY","LU1023059063.AUD","LU0320765489.SGD","IE00BLSP4452.SGD","LU0965509010.AUD","LU2362541273.HKD","LU0106261372.USD"],"gpt_icon":0},{"id":"2512410702","title":"Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies’ Board of Directors at 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2512410702","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512410702?lang=en_us&edition=fundamental","pubTime":"2025-02-19 22:00","pubTimestamp":1739973600,"startTime":"0","endTime":"0","summary":"Issues Letter to Fellow Shareholders Detailing Why Truly Independent Voices – Including a Shareholder Representative – Are Needed in the Dynavax Boardroom. Highlights Concerns that Company’s Misguided Acquisition Strategy Will Destroy Value and Prevent Dynavax from Maximizing the Benefit of Heplisav for Shareholders and Patients. In Deep Track’s View, Focusing on Heplisav Could Result in Nearly $2 Billion of Cash Being Returned to Shareholders by the End of 2030. Details Board’s Poor Governance, Reactive Entrenchment Maneuvers, and Unwillingness to Work Constructively. Believes Its Slate of Director Nominees Would Collectively Bring Valuable Shareholder Perspective and Independence as Well as Necessary Life Sciences Background, Capital Allocation Experience and Operational Expertise to the Dynavax Board. GREENWICH, Conn., February 19, 2025----Deep Track Capital, LP, , one of the largest shareholders of Dynavax Technologies Corporation  , with ownership of approximately 13.53% of the Co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/deep-track-capital-nominates-four-140000192.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QID","BK4533","IE00BFXG1179.USD","SNY","BK4007","QLD","NQmain","BK4551","BK4532","SQQQ","MNQmain","PSQ","BK4585",".IXIC","BK4139","BK4588","TQQQ","BK4548","MRNA","BK4534","AVTE","USAW.SI","USJW.SI","BK4568","NVIW.SI","TSYW.SI","GBT","TARS","ZNTL","DVAX","BK4501","BK4539"],"gpt_icon":1},{"id":"2512633831","title":"SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag","url":"https://stock-news.laohu8.com/highlight/detail?id=2512633831","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512633831?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:40","pubTimestamp":1739882400,"startTime":"0","endTime":"0","summary":"Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application  seeking approval for Dupixent for treating bullous pemphigoid , a chronic, debilitating and relapsing skin disease.With the FDA granting a priority review status to the sBLA, a decision is expected by June 20, 2025.The sBLA is based on data from a pivotal study that demonstrated that Dupixent led to significant improvements in sustained disease remission compared to placebo in adult patients with moderate-to-severe BP.Sanofi’s stock has risen 18% in the past year against a decrease of 7.9% for the industry.BP is an inflammatory skin condition primarily occurring due to type 2 inflammation. The disease, which mostly occurs in older adults, is characterized by large fluid-filled blisters on the skin which can be itchy and painful, reddening of the skin and painful lesions. If approved for BP, Dupixent will become the first medicine approved as a targeted treatment f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sny-regns-dupixent-sbla-skin-124000832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BP","BK4566","BK4583","BK4532","LU0320765646.SGD","LU2362540622.SGD","LU2023250504.SGD","LU0823416689.USD","BK4201","LU2089984988.USD","LU1839511570.USD","BK4585","LU2468319806.SGD","IE00BFXG1179.USD","LU1829250122.USD","BK4548","LU2362541273.HKD","LU1066051498.USD","IE00B19Z3B42.SGD","LU2237438978.USD","LU2362541513.USD","LU1917777945.USD","IE0002270589.USD","LU1585245621.USD","IE00BZ1G4Q59.USD","LU1974910355.USD","BK4007","BK4568","IE00B19Z3581.USD","LU0320765992.SGD","BK4578","LU1162221912.USD","SNY","LU1066053197.SGD","LU0889565916.HKD","LU1571399168.USD","LU0234570918.USD","REGN","LU0289739699.SGD","IE00BSNM7G36.USD","LU0053666078.USD","ALNY","IE00B7SZLL34.SGD","GILD","IE00B3T34201.USD","LU0109394709.USD","LU2087621335.USD","LU0882574055.USD","BK4588","BK4550"],"gpt_icon":0},{"id":"2512153133","title":"Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Bullous Pemphigoid","url":"https://stock-news.laohu8.com/highlight/detail?id=2512153133","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512153133?lang=en_us&edition=fundamental","pubTime":"2025-02-18 19:10","pubTimestamp":1739877000,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals and Sanofi have won Food and Drug Administration priority review of their application seeking expanded approval of their blockbuster anti-inflammatory drug Dupixent for adults with the chronic skin disease bullous pemphigoid.Regeneron and Sanofi on Tuesday said the speedy FDA review is based on study results showing significant improvements in sustained disease remission with Dupixent compared with placebo.The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period. The agency has set a target action date of June 20 for the application.Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 inflammation characterized by intense itch and blisters, reddening of the skin and painful lesions.Tarrytown","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2362540622.SGD","LU0114720955.EUR","LU0823416689.USD","LU2237438978.USD","LU0053666078.USD","LU2089984988.USD","LU0109394709.USD","LU2023250504.SGD","LU0882574055.USD","LU2362541513.USD","LU1917777945.USD","BK4007","LU1974910355.USD","REGN","BK4588","BK4585","LU2468319806.SGD","LU0889565916.HKD","SNY","IE00BFXG1179.USD","LU0058720904.USD","LU0289739699.SGD","LU2362541273.HKD","SNYNF","LU2106854487.HKD","LU0320765992.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SNY\",params:#limit:5,,,undefined,":[{"date":"2025-05-09","symbol":"SNY","amount":2.212154,"announcedDate":"2025-04-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-09","defaultRemindTime":1746797400000,"name":"赛诺菲安万特","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-12","payableDate":"2025-05-09","currency":"USD","dateTimestamp":1746763200000,"payDate":"2025-06-12"},{"market":"US","date":"2025-04-24","symbol":"SNY","fiscalQuarterEnding":"2025/03","expectedEps":0.9,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1745467200000,"reportTimeType":"pre","actualEps":0.94},{"market":"US","date":"2025-01-30","symbol":"SNY","fiscalQuarterEnding":"2024/12","expectedEps":0.71,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1738213200000,"reportTimeType":"pre","actualEps":0.7},{"market":"US","date":"2024-10-25","symbol":"SNY","fiscalQuarterEnding":"2024/09","expectedEps":1.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1729828800000,"reportTimeType":"pre","actualEps":1.57},{"date":"2024-09-12","symbol":"SNY","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1726128000000,"name":null,"time":"Pre-Market","dateTimestamp":1726113600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SNY\",market:\"US\",,,undefined,":[{"executeDate":"2015-05-06","recordDate":"2015-05-08","paymentDate":"2015-06-02","value":1.086507,"currency":"USD"},{"executeDate":"2016-05-05","recordDate":"2016-05-09","paymentDate":"2016-06-01","value":1.124297,"currency":"USD"},{"executeDate":"2017-05-11","recordDate":"2017-05-15","paymentDate":"2017-06-07","value":1.053962,"currency":"USD"},{"executeDate":"2018-05-09","recordDate":"2018-05-10","paymentDate":"2018-06-04","value":1.252612,"currency":"USD"},{"executeDate":"2019-05-07","recordDate":"2019-05-08","paymentDate":"2019-05-31","value":1.739462,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SNY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.2857,"hold":0.2857,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2857,"analysts":7,"updateTime":1742616000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SNY\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SNY","date":"2025-04-25","current":17.94759,"percent":0.535188,"low":7.700371,"twenty":10.042807,"median":17.659092,"eighty":24.198495,"high":35.240461,"avg":17.771482,"sd":6.914677,"marketCap":128365926735.55},"quantilePoints":[{"date":"2020-05-01","current":33.287209,"twenty":10.936939,"median":22.288206,"eighty":27.915788,"marketCap":122748871163.92},{"date":"2020-05-08","current":33.429348,"twenty":10.947749,"median":22.313398,"eighty":28.361828,"marketCap":121627238914.58},{"date":"2020-05-15","current":32.595691,"twenty":10.949613,"median":22.330456,"eighty":28.489712,"marketCap":118247569927.49},{"date":"2020-05-22","current":32.461152,"twenty":10.950809,"median":22.368981,"eighty":28.664689,"marketCap":118529173787.58},{"date":"2020-05-29","current":32.711543,"twenty":10.957417,"median":22.45326,"eighty":28.739014,"marketCap":121900047291.83},{"date":"2020-06-05","current":33.320704,"twenty":10.961705,"median":22.504413,"eighty":28.869762,"marketCap":126404479866.46},{"date":"2020-06-12","current":33.26848,"twenty":10.97427,"median":22.552737,"eighty":29.165734,"marketCap":125312894610.63},{"date":"2020-06-19","current":35.174448,"twenty":10.980961,"median":22.560851,"eighty":29.253683,"marketCap":131987852645.25},{"date":"2020-06-26","current":34.045816,"twenty":10.987268,"median":22.616571,"eighty":29.711727,"marketCap":127924643785.45},{"date":"2020-07-02","current":34.367214,"twenty":10.994274,"median":22.648355,"eighty":29.771242,"marketCap":129509727296.23},{"date":"2020-07-10","current":33.233448,"twenty":10.9995,"median":22.663506,"eighty":32.384166,"marketCap":126030678803.03},{"date":"2020-07-17","current":34.840553,"twenty":11.002375,"median":22.680357,"eighty":32.642032,"marketCap":133469182626.29},{"date":"2020-07-24","current":33.192336,"twenty":11.004309,"median":22.714228,"eighty":32.855777,"marketCap":129403011819.03},{"date":"2020-07-31","current":10.079688,"twenty":10.9995,"median":22.705861,"eighty":32.972702,"marketCap":131609513547.85},{"date":"2020-08-07","current":9.946507,"twenty":10.971294,"median":22.66842,"eighty":32.855777,"marketCap":129396034746.58},{"date":"2020-08-14","current":9.727952,"twenty":10.948867,"median":22.658549,"eighty":32.749663,"marketCap":127031956635.12},{"date":"2020-08-21","current":9.828123,"twenty":10.929747,"median":22.644775,"eighty":32.720989,"marketCap":127780651499.59},{"date":"2020-08-28","current":9.679005,"twenty":10.883242,"median":22.578254,"eighty":32.71485,"marketCap":127069323852.74},{"date":"2020-09-04","current":9.512813,"twenty":10.85502,"median":22.559456,"eighty":32.642032,"marketCap":123841606541.64},{"date":"2020-09-11","current":9.96472,"twenty":10.823199,"median":22.547298,"eighty":32.561309,"marketCap":130185382800.66},{"date":"2020-09-18","current":10.067167,"twenty":10.684765,"median":22.493564,"eighty":32.490302,"marketCap":131820291420.1},{"date":"2020-09-25","current":9.858857,"twenty":10.595525,"median":22.444418,"eighty":32.458162,"marketCap":126422921729.99},{"date":"2020-10-02","current":9.798527,"twenty":10.526117,"median":22.342652,"eighty":32.407337,"marketCap":126679565248.92},{"date":"2020-10-09","current":9.824708,"twenty":10.410161,"median":22.324584,"eighty":32.285505,"marketCap":128128683268.34},{"date":"2020-10-16","current":9.793052,"twenty":10.315413,"median":22.302943,"eighty":31.257628,"marketCap":126623612278.58},{"date":"2020-10-23","current":9.441308,"twenty":10.238589,"median":22.261435,"eighty":29.811136,"marketCap":123347203619.79},{"date":"2020-10-30","current":8.661295,"twenty":10.199611,"median":22.234806,"eighty":29.773341,"marketCap":113280166110.01},{"date":"2020-11-06","current":9.327376,"twenty":10.132097,"median":22.205679,"eighty":29.767042,"marketCap":124442629581.55},{"date":"2020-11-13","current":9.605003,"twenty":10.089923,"median":22.112471,"eighty":29.762798,"marketCap":127479835927.15},{"date":"2020-11-20","current":9.6106,"twenty":10.079688,"median":22.081393,"eighty":29.73408,"marketCap":127917182157.26},{"date":"2020-11-27","current":9.538955,"twenty":10.057978,"median":22.005256,"eighty":29.655002,"marketCap":127995801275.71},{"date":"2020-12-04","current":9.358721,"twenty":10.040076,"median":21.945075,"eighty":29.437865,"marketCap":127467141893.2},{"date":"2020-12-11","current":8.790033,"twenty":10.022546,"median":21.91943,"eighty":29.296005,"marketCap":119489512407.95},{"date":"2020-12-18","current":8.844887,"twenty":9.993694,"median":21.901999,"eighty":29.279125,"marketCap":121396802063.1},{"date":"2020-12-24","current":8.769883,"twenty":9.976103,"median":21.881466,"eighty":29.245202,"marketCap":119941986349.01},{"date":"2020-12-31","current":8.810183,"twenty":9.961936,"median":21.873052,"eighty":29.24273,"marketCap":120950078152.91},{"date":"2021-01-08","current":8.820259,"twenty":9.95106,"median":21.862976,"eighty":29.210969,"marketCap":121221849881.21},{"date":"2021-01-15","current":9.126992,"twenty":9.936588,"median":21.828735,"eighty":29.197581,"marketCap":123845036018.62},{"date":"2021-01-22","current":9.119156,"twenty":9.919292,"median":21.813001,"eighty":29.173346,"marketCap":124582207014},{"date":"2021-01-29","current":8.636715,"twenty":9.906894,"median":21.809329,"eighty":29.059102,"marketCap":117661873131.83},{"date":"2021-02-05","current":8.176599,"twenty":9.88162,"median":21.779975,"eighty":28.982923,"marketCap":120922774999.4},{"date":"2021-02-12","current":7.987538,"twenty":9.856239,"median":21.763827,"eighty":28.950951,"marketCap":119014418424.43},{"date":"2021-02-19","current":7.870014,"twenty":9.848372,"median":21.763595,"eighty":28.901957,"marketCap":117391358460.33},{"date":"2021-02-26","current":7.746359,"twenty":9.840411,"median":21.746147,"eighty":28.832667,"marketCap":115225330598.91},{"date":"2021-03-05","current":7.860937,"twenty":9.827943,"median":21.729717,"eighty":28.787173,"marketCap":115132662522.04},{"date":"2021-03-12","current":8.118972,"twenty":9.808685,"median":21.685029,"eighty":28.757776,"marketCap":119210132761.26},{"date":"2021-03-19","current":8.502978,"twenty":9.798186,"median":21.612115,"eighty":28.742096,"marketCap":124417528040.94},{"date":"2021-03-26","current":8.489771,"twenty":9.792219,"median":21.598158,"eighty":28.727957,"marketCap":123096173961.55},{"date":"2021-04-01","current":8.553964,"twenty":9.788159,"median":21.54258,"eighty":28.711437,"marketCap":123735063715.73},{"date":"2021-04-09","current":8.641332,"twenty":9.782356,"median":21.526019,"eighty":28.694903,"marketCap":126246626546.64},{"date":"2021-04-16","current":8.636253,"twenty":9.769654,"median":21.512492,"eighty":28.66049,"marketCap":127185060180.88},{"date":"2021-04-23","current":8.669778,"twenty":9.761091,"median":21.479045,"eighty":28.625112,"marketCap":128556561372.57},{"date":"2021-04-30","current":8.936356,"twenty":9.755206,"median":21.457669,"eighty":28.539275,"marketCap":131116008424.15},{"date":"2021-05-07","current":8.761308,"twenty":9.751942,"median":21.433287,"eighty":28.492512,"marketCap":129875631253.04},{"date":"2021-05-14","current":8.892563,"twenty":9.741584,"median":21.426198,"eighty":28.475014,"marketCap":131645337996.12},{"date":"2021-05-21","current":9.047404,"twenty":9.729833,"median":21.41999,"eighty":28.415141,"marketCap":134492606805.61},{"date":"2021-05-28","current":9.019717,"twenty":9.710422,"median":21.40835,"eighty":28.40452,"marketCap":134081034734.92},{"date":"2021-06-04","current":8.826935,"twenty":9.707463,"median":21.392314,"eighty":28.379325,"marketCap":130991765454.43},{"date":"2021-06-11","current":9.116284,"twenty":9.694395,"median":21.363939,"eighty":28.361828,"marketCap":134500207706.54},{"date":"2021-06-18","current":9.021943,"twenty":9.679005,"median":21.290156,"eighty":28.230746,"marketCap":130457184786.01},{"date":"2021-06-25","current":9.04963,"twenty":9.672117,"median":21.229467,"eighty":28.073267,"marketCap":131826509965.36},{"date":"2021-07-02","current":9.013739,"twenty":9.660792,"median":21.196129,"eighty":27.996278,"marketCap":130199639608.01},{"date":"2021-07-09","current":8.944008,"twenty":9.658829,"median":21.16444,"eighty":27.931886,"marketCap":129422313900.82},{"date":"2021-07-16","current":9.010663,"twenty":9.638085,"median":21.140332,"eighty":27.848598,"marketCap":129770992211.6},{"date":"2021-07-23","current":9.031172,"twenty":9.62122,"median":21.117164,"eighty":27.80391,"marketCap":129576758627.22},{"date":"2021-07-30","current":18.87536,"twenty":9.610467,"median":21.085355,"eighty":27.796937,"marketCap":129351074870.7},{"date":"2021-08-06","current":18.73975,"twenty":9.613461,"median":21.013453,"eighty":27.749237,"marketCap":127349176618.04},{"date":"2021-08-13","current":19.000477,"twenty":9.62122,"median":20.964049,"eighty":27.709316,"marketCap":129532398703.09},{"date":"2021-08-20","current":19.713131,"twenty":9.626758,"median":20.922915,"eighty":27.702194,"marketCap":133040601577.1},{"date":"2021-08-27","current":19.159086,"twenty":9.631579,"median":20.849323,"eighty":27.682689,"marketCap":130505881690.84},{"date":"2021-09-03","current":19.087386,"twenty":9.636484,"median":20.812207,"eighty":27.640133,"marketCap":131037228600.12},{"date":"2021-09-10","current":17.788527,"twenty":9.637931,"median":20.810313,"eighty":27.621196,"marketCap":121557039339.96},{"date":"2021-09-17","current":17.718998,"twenty":9.644258,"median":20.781658,"eighty":27.597623,"marketCap":120158061709.12},{"date":"2021-09-24","current":17.821119,"twenty":9.653374,"median":20.756596,"eighty":27.571856,"marketCap":120553399377.05},{"date":"2021-10-01","current":17.949313,"twenty":9.657986,"median":20.686673,"eighty":27.533829,"marketCap":120210038226.29},{"date":"2021-10-08","current":18.316512,"twenty":9.65882,"median":20.60166,"eighty":27.49647,"marketCap":122456300914.25},{"date":"2021-10-15","current":18.21668,"twenty":9.659965,"median":20.367209,"eighty":27.481537,"marketCap":122085570969.84},{"date":"2021-10-22","current":18.492625,"twenty":9.660762,"median":19.534967,"eighty":27.418547,"marketCap":124266480579.27},{"date":"2021-10-29","current":17.57188,"twenty":9.660792,"median":19.400258,"eighty":27.363912,"marketCap":125449567069.84},{"date":"2021-11-05","current":17.984594,"twenty":9.662246,"median":19.19059,"eighty":27.343794,"marketCap":128307008370.7},{"date":"2021-11-12","current":18.139856,"twenty":9.664147,"median":19.148222,"eighty":27.315537,"marketCap":128214619445.91},{"date":"2021-11-19","current":18.074795,"twenty":9.669177,"median":19.129754,"eighty":27.3008,"marketCap":126337351612.14},{"date":"2021-11-26","current":17.283895,"twenty":9.672117,"median":19.062399,"eighty":27.290992,"marketCap":120754520924.52},{"date":"2021-12-03","current":17.031784,"twenty":9.672185,"median":18.974404,"eighty":27.274231,"marketCap":118697631154.76},{"date":"2021-12-10","current":17.593219,"twenty":9.673996,"median":18.883829,"eighty":27.261649,"marketCap":122887806332.16},{"date":"2021-12-17","current":17.666414,"twenty":9.676585,"median":18.822313,"eighty":27.226753,"marketCap":122981663791.86},{"date":"2021-12-23","current":17.924629,"twenty":9.677102,"median":18.797147,"eighty":27.187184,"marketCap":125231028798.23},{"date":"2021-12-31","current":18.010023,"twenty":9.680432,"median":18.68789,"eighty":27.152672,"marketCap":126457276638.23},{"date":"2022-01-07","current":18.01409,"twenty":9.687791,"median":18.583882,"eighty":27.099359,"marketCap":126127227506.24},{"date":"2022-01-14","current":18.425049,"twenty":9.694395,"median":18.458837,"eighty":27.042911,"marketCap":129932901404.91},{"date":"2022-01-21","current":18.490113,"twenty":9.694395,"median":18.493429,"eighty":27.028616,"marketCap":129474826588.41},{"date":"2022-01-28","current":19.165142,"twenty":9.694395,"median":18.494232,"eighty":27.028595,"marketCap":132074546389.11},{"date":"2022-02-04","current":18.213402,"twenty":9.69608,"median":18.572578,"eighty":27.025402,"marketCap":129696764676.74},{"date":"2022-02-11","current":18.927495,"twenty":9.697119,"median":18.616113,"eighty":27.010232,"marketCap":134335997389.37},{"date":"2022-02-18","current":18.766118,"twenty":9.697119,"median":18.604323,"eighty":27.010232,"marketCap":132345369395.97},{"date":"2022-02-25","current":18.833821,"twenty":9.697119,"median":18.575534,"eighty":27.010232,"marketCap":132044689275.57},{"date":"2022-03-04","current":17.617959,"twenty":9.697119,"median":18.491369,"eighty":27.010232,"marketCap":119664437682.82},{"date":"2022-03-11","current":18.783661,"twenty":9.697119,"median":18.43883,"eighty":27.010232,"marketCap":127973204254.43},{"date":"2022-03-18","current":18.717451,"twenty":9.697119,"median":18.43883,"eighty":27.010232,"marketCap":128848117335.18},{"date":"2022-03-25","current":18.683343,"twenty":9.697119,"median":18.43883,"eighty":27.010232,"marketCap":127751282161.3},{"date":"2022-04-01","current":18.889374,"twenty":9.697119,"median":18.43883,"eighty":27.010232,"marketCap":129744565958.06},{"date":"2022-04-08","current":20.960102,"twenty":9.697119,"median":18.43883,"eighty":27.010232,"marketCap":141869390625.41},{"date":"2022-04-14","current":20.695242,"twenty":9.697119,"median":18.43883,"eighty":27.010232,"marketCap":139183497682.91},{"date":"2022-04-22","current":20.346108,"twenty":9.697119,"median":18.43883,"eighty":27.010232,"marketCap":136481434838.85},{"date":"2022-04-29","current":18.952765,"twenty":9.697119,"median":18.43883,"eighty":27.010232,"marketCap":133142723720.1},{"date":"2022-05-06","current":18.179144,"twenty":9.697119,"median":18.493429,"eighty":27.010232,"marketCap":128384549744.68},{"date":"2022-05-13","current":18.692394,"twenty":9.697119,"median":18.527753,"eighty":27.010232,"marketCap":129700736023.73},{"date":"2022-05-20","current":19.16256,"twenty":9.697119,"median":18.604323,"eighty":27.010232,"marketCap":134758546837.22},{"date":"2022-05-27","current":19.177546,"twenty":9.697119,"median":18.665261,"eighty":27.010232,"marketCap":136958987699.81},{"date":"2022-06-03","current":18.744225,"twenty":9.697119,"median":18.681313,"eighty":27.010232,"marketCap":133921762001.07},{"date":"2022-06-10","current":18.146643,"twenty":9.697119,"median":18.685349,"eighty":27.010232,"marketCap":127291929717.98},{"date":"2022-06-17","current":17.640852,"twenty":9.697119,"median":18.685349,"eighty":27.010232,"marketCap":123044805550.91},{"date":"2022-06-24","current":18.83789,"twenty":9.696859,"median":18.692394,"eighty":27.014025,"marketCap":132461365342.83},{"date":"2022-07-01","current":18.293193,"twenty":9.696859,"median":18.693435,"eighty":27.014025,"marketCap":126838383992.09},{"date":"2022-07-08","current":18.63272,"twenty":9.696859,"median":18.693435,"eighty":27.014025,"marketCap":126418025181.68},{"date":"2022-07-15","current":18.795918,"twenty":9.696859,"median":18.717451,"eighty":27.014025,"marketCap":126431471445.01},{"date":"2022-07-22","current":18.263208,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":124455681540.58},{"date":"2022-07-29","current":18.321107,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":124140260314.16},{"date":"2022-08-05","current":18.377647,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":123992191551.9},{"date":"2022-08-12","current":16.132936,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":109885258896.75},{"date":"2022-08-19","current":15.415581,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":102816971778.11},{"date":"2022-08-26","current":15.459,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":102642813930.03},{"date":"2022-09-02","current":15.37405,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":102457677511.04},{"date":"2022-09-09","current":15.328743,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":102237792167.67},{"date":"2022-09-16","current":15.453336,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":102882856127.48},{"date":"2022-09-23","current":14.877565,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":96093011237.72},{"date":"2022-09-30","current":14.800166,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":96408611153.17},{"date":"2022-10-07","current":15.132414,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":98274151179.98},{"date":"2022-10-14","current":15.398591,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":99690906745.93},{"date":"2022-10-21","current":15.398591,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":100326441165.16},{"date":"2022-10-28","current":16.846401,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":107356651323.46},{"date":"2022-11-04","current":17.17473,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":109112652999.6},{"date":"2022-11-11","current":16.109615,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":106637600025.82},{"date":"2022-11-18","current":16.83559,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":111812739546.11},{"date":"2022-11-25","current":17.129097,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":114152420880.73},{"date":"2022-12-02","current":16.782758,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":112782528627.45},{"date":"2022-12-09","current":17.361946,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":117264953276.43},{"date":"2022-12-16","current":17.144751,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":116510134592.3},{"date":"2022-12-23","current":17.802208,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":121183588329.26},{"date":"2022-12-30","current":17.579142,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":120406882967.83},{"date":"2023-01-06","current":17.829602,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":121279894677.35},{"date":"2023-01-13","current":17.841342,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":123710007946.55},{"date":"2023-01-20","current":17.659092,"twenty":9.696859,"median":18.719457,"eighty":27.014025,"marketCap":122645342505.42},{"date":"2023-01-27","current":17.429425,"twenty":9.703429,"median":18.719457,"eighty":27.014025,"marketCap":121260511615.28},{"date":"2023-02-03","current":12.687149,"twenty":9.709538,"median":18.719457,"eighty":27.014025,"marketCap":115251355422.68},{"date":"2023-02-10","current":13.217643,"twenty":9.726396,"median":18.719457,"eighty":27.014025,"marketCap":118159855219.99},{"date":"2023-02-17","current":13.277249,"twenty":9.741642,"median":18.719457,"eighty":27.014025,"marketCap":118515515804.01},{"date":"2023-02-24","current":13.411211,"twenty":9.752083,"median":18.719457,"eighty":27.014025,"marketCap":118448244308.93},{"date":"2023-03-03","current":13.302322,"twenty":9.756767,"median":18.719457,"eighty":27.014025,"marketCap":118034490740.94},{"date":"2023-03-10","current":13.357512,"twenty":9.764714,"median":18.719457,"eighty":27.014025,"marketCap":119257397037.12},{"date":"2023-03-17","current":13.394803,"twenty":9.773462,"median":18.719457,"eighty":27.014025,"marketCap":119526591543.55},{"date":"2023-03-24","current":14.48369,"twenty":9.785178,"median":18.719457,"eighty":27.014025,"marketCap":130424881067.13},{"date":"2023-03-31","current":14.952061,"twenty":9.790694,"median":18.718645,"eighty":27.010232,"marketCap":135988374469.8},{"date":"2023-04-06","current":15.280218,"twenty":9.798413,"median":18.718645,"eighty":27.010232,"marketCap":139686260171.45},{"date":"2023-04-14","current":15.221476,"twenty":9.80991,"median":18.730688,"eighty":27.025402,"marketCap":140825574178.82},{"date":"2023-04-19","current":15.209543,"twenty":9.82744,"median":18.731112,"eighty":27.026041,"marketCap":139558349488.11},{"date":"2023-04-27","current":15.21474,"twenty":9.850092,"median":18.73173,"eighty":27.027318,"marketCap":140140612943.9},{"date":"2023-05-05","current":15.175888,"twenty":9.902113,"median":18.731826,"eighty":27.028595,"marketCap":139552044885.56},{"date":"2023-05-12","current":14.838181,"twenty":9.939677,"median":18.731826,"eighty":27.028595,"marketCap":135403671391.13},{"date":"2023-05-19","current":15.184854,"twenty":9.959028,"median":18.731826,"eighty":27.028595,"marketCap":136642429723.27},{"date":"2023-05-26","current":14.853124,"twenty":9.978835,"median":18.733652,"eighty":27.028599,"marketCap":133126940240.24},{"date":"2023-06-02","current":14.192653,"twenty":10.040758,"median":18.733652,"eighty":27.028599,"marketCap":127343787455.44},{"date":"2023-06-09","current":14.256612,"twenty":10.09699,"median":18.733652,"eighty":27.028599,"marketCap":128372490395.43},{"date":"2023-06-16","current":14.295467,"twenty":10.208772,"median":18.72486,"eighty":27.028599,"marketCap":130508209942.1},{"date":"2023-06-23","current":14.734821,"twenty":10.181908,"median":18.697387,"eighty":27.028603,"marketCap":134961533039.24},{"date":"2023-06-30","current":14.675045,"twenty":10.181908,"median":18.683343,"eighty":27.028603,"marketCap":133521342889.49},{"date":"2023-07-07","current":14.039924,"twenty":10.181908,"median":18.651241,"eighty":27.028603,"marketCap":127451273212.04},{"date":"2023-07-14","current":14.002564,"twenty":10.181908,"median":18.628706,"eighty":27.028603,"marketCap":130982117535.26},{"date":"2023-07-21","current":14.736316,"twenty":10.181908,"median":18.609955,"eighty":27.028603,"marketCap":137261916493.54},{"date":"2023-07-28","current":14.230057,"twenty":10.155044,"median":18.575133,"eighty":27.028608,"marketCap":130696325708.32},{"date":"2023-08-04","current":13.64955,"twenty":10.155044,"median":18.53333,"eighty":27.028608,"marketCap":128783719369.32},{"date":"2023-08-11","current":14.107345,"twenty":10.155044,"median":18.465688,"eighty":27.028608,"marketCap":133909438393.92},{"date":"2023-08-18","current":14.257236,"twenty":10.155044,"median":18.417461,"eighty":27.028608,"marketCap":133639295738.06},{"date":"2023-08-25","current":14.360528,"twenty":10.155044,"median":18.371061,"eighty":27.028608,"marketCap":134024340566.45},{"date":"2023-09-01","current":14.34598,"twenty":10.155044,"median":18.34457,"eighty":27.028608,"marketCap":134077344689.8},{"date":"2023-09-08","current":14.597664,"twenty":10.155044,"median":18.325923,"eighty":27.028608,"marketCap":134604678073.84},{"date":"2023-09-15","current":14.95555,"twenty":10.155044,"median":18.296091,"eighty":27.016307,"marketCap":137463437822.93},{"date":"2023-09-22","current":14.853801,"twenty":10.12818,"median":18.276078,"eighty":27.020855,"marketCap":136484543397.31},{"date":"2023-09-29","current":14.763602,"twenty":10.12818,"median":18.246983,"eighty":26.983029,"marketCap":134423031209.85},{"date":"2023-10-06","current":14.868349,"twenty":10.12818,"median":18.218159,"eighty":26.938973,"marketCap":134892153493.37},{"date":"2023-10-13","current":15.040019,"twenty":10.12818,"median":18.16832,"eighty":26.598464,"marketCap":136737545848.28},{"date":"2023-10-20","current":14.380784,"twenty":10.12818,"median":18.144978,"eighty":26.402781,"marketCap":131062102932.84},{"date":"2023-10-27","current":11.85036,"twenty":10.092665,"median":18.111628,"eighty":26.025777,"marketCap":107534279335.51},{"date":"2023-11-03","current":11.80423,"twenty":10.092665,"median":18.07332,"eighty":25.817137,"marketCap":113606320100.85},{"date":"2023-11-10","current":11.775378,"twenty":10.092665,"median":18.059836,"eighty":25.817137,"marketCap":114360557197.64},{"date":"2023-11-17","current":11.879108,"twenty":10.092665,"median":18.023837,"eighty":25.817137,"marketCap":116984566837.93},{"date":"2023-11-24","current":11.946878,"twenty":10.092665,"median":18.009006,"eighty":25.817137,"marketCap":118113843833.15},{"date":"2023-12-01","current":11.863894,"twenty":10.092665,"median":17.972228,"eighty":25.817137,"marketCap":117306211282.58},{"date":"2023-12-08","current":11.912301,"twenty":10.09699,"median":17.952065,"eighty":25.812238,"marketCap":116514105188.26},{"date":"2023-12-15","current":12.129442,"twenty":10.09699,"median":17.934507,"eighty":25.812238,"marketCap":120907663627.27},{"date":"2023-12-22","current":12.356264,"twenty":10.09699,"median":17.886813,"eighty":25.812238,"marketCap":123141571763.22},{"date":"2023-12-29","current":12.414352,"twenty":10.092665,"median":17.852857,"eighty":25.817137,"marketCap":124666059594.59},{"date":"2024-01-05","current":12.928851,"twenty":10.088339,"median":17.827036,"eighty":25.822036,"marketCap":128452561703.01},{"date":"2024-01-12","current":13.228975,"twenty":10.088339,"median":17.806558,"eighty":25.822036,"marketCap":131304891825.05},{"date":"2024-01-19","current":13.006481,"twenty":10.084014,"median":17.776767,"eighty":25.826935,"marketCap":128114681751.41},{"date":"2024-01-26","current":12.735372,"twenty":10.088339,"median":17.745072,"eighty":25.822036,"marketCap":125131555256.31},{"date":"2024-02-02","current":20.334039,"twenty":10.088339,"median":17.71521,"eighty":25.822036,"marketCap":119118906599.05},{"date":"2024-02-09","current":20.085581,"twenty":10.088339,"median":17.71521,"eighty":25.822036,"marketCap":116751493787.94},{"date":"2024-02-16","current":20.076293,"twenty":10.088339,"median":17.71521,"eighty":25.822036,"marketCap":116634730314.15},{"date":"2024-02-23","current":20.830953,"twenty":10.088339,"median":17.71521,"eighty":25.822036,"marketCap":121673497945.92},{"date":"2024-03-01","current":20.187328,"twenty":10.092665,"median":17.717104,"eighty":25.817137,"marketCap":117837605321.59},{"date":"2024-03-08","current":20.275189,"twenty":10.092665,"median":17.717104,"eighty":25.817137,"marketCap":119656853104.92},{"date":"2024-03-15","current":20.393108,"twenty":10.092665,"median":17.717104,"eighty":25.817137,"marketCap":119946394721.71},{"date":"2024-03-22","current":20.497155,"twenty":10.092665,"median":17.717104,"eighty":25.817137,"marketCap":120191807946.57},{"date":"2024-03-28","current":21.03126,"twenty":10.092665,"median":17.717104,"eighty":25.817137,"marketCap":122670991700.15},{"date":"2024-04-05","current":20.194264,"twenty":10.088339,"median":17.71521,"eighty":25.822036,"marketCap":118454296559.85},{"date":"2024-04-12","current":19.993107,"twenty":10.088339,"median":17.71521,"eighty":25.822036,"marketCap":115628981743.6},{"date":"2024-04-19","current":20.090217,"twenty":10.088339,"median":17.71521,"eighty":25.822036,"marketCap":115682634323.95},{"date":"2024-04-26","current":25.102236,"twenty":10.092665,"median":17.717104,"eighty":25.817137,"marketCap":122028864510.98},{"date":"2024-05-03","current":25.121496,"twenty":10.092665,"median":17.717104,"eighty":25.817137,"marketCap":121965711156.52},{"date":"2024-05-10","current":25.955211,"twenty":10.092665,"median":17.717104,"eighty":25.881185,"marketCap":126909542740.01},{"date":"2024-05-17","current":24.564329,"twenty":10.092665,"median":17.717104,"eighty":25.881185,"marketCap":121166222484.78},{"date":"2024-05-24","current":24.660746,"twenty":10.092665,"median":17.717104,"eighty":25.881185,"marketCap":121128331641.95},{"date":"2024-05-31","current":24.726861,"twenty":10.092665,"median":17.717104,"eighty":25.881185,"marketCap":121676961247.02},{"date":"2024-06-07","current":25.104265,"twenty":10.092665,"median":17.717104,"eighty":25.881185,"marketCap":123964258787.81},{"date":"2024-06-14","current":23.809521,"twenty":10.092665,"median":17.717104,"eighty":25.881185,"marketCap":116305279179.76},{"date":"2024-06-21","current":24.137339,"twenty":10.088339,"median":17.71521,"eighty":25.90586,"marketCap":117375957434.63},{"date":"2024-06-28","current":24.776447,"twenty":10.079688,"median":17.696545,"eighty":25.961437,"marketCap":120367749389.79},{"date":"2024-07-05","current":25.051924,"twenty":10.079688,"median":17.696545,"eighty":25.961437,"marketCap":122903385527.57},{"date":"2024-07-12","current":26.005076,"twenty":10.079688,"median":17.696545,"eighty":25.984495,"marketCap":128286809560.82},{"date":"2024-07-15","current":25.462386,"twenty":10.079688,"median":17.696545,"eighty":25.984495,"marketCap":126116902211.31},{"date":"2024-08-02","current":28.58221,"twenty":10.045539,"median":17.667431,"eighty":25.970775,"marketCap":129963975586.71},{"date":"2024-08-09","current":28.611937,"twenty":10.045539,"median":17.667431,"eighty":26.395222,"marketCap":131603672136.16},{"date":"2024-08-16","current":29.365903,"twenty":10.045539,"median":17.667431,"eighty":26.965608,"marketCap":135991482271.53},{"date":"2024-08-23","current":29.827758,"twenty":10.045539,"median":17.667431,"eighty":27.30154,"marketCap":139679917173.16},{"date":"2024-08-30","current":30.083408,"twenty":10.045539,"median":17.667431,"eighty":27.737312,"marketCap":140486982478.95},{"date":"2024-09-06","current":31.076279,"twenty":10.045539,"median":17.667431,"eighty":27.755808,"marketCap":145252320920.18},{"date":"2024-09-13","current":30.737395,"twenty":10.045539,"median":17.667431,"eighty":28.017403,"marketCap":143002491189.58},{"date":"2024-09-20","current":30.78296,"twenty":10.045539,"median":17.667431,"eighty":28.416222,"marketCap":144554419337.27},{"date":"2024-09-27","current":30.616469,"twenty":10.045539,"median":17.667431,"eighty":28.416222,"marketCap":144270741555.83},{"date":"2024-10-04","current":30.241865,"twenty":10.045539,"median":17.667431,"eighty":28.439522,"marketCap":140433638887.54},{"date":"2024-10-11","current":29.775602,"twenty":10.045539,"median":17.667431,"eighty":28.439522,"marketCap":137150593697.15},{"date":"2024-10-18","current":29.977793,"twenty":10.045539,"median":17.667431,"eighty":28.439522,"marketCap":136855848164.59},{"date":"2024-10-25","current":29.757762,"twenty":10.045539,"median":17.667431,"eighty":28.439522,"marketCap":135513851100.67},{"date":"2024-10-31","current":27.016329,"twenty":10.045539,"median":17.667431,"eighty":28.017403,"marketCap":132177608883.82},{"date":"2024-11-08","current":26.635368,"twenty":10.044628,"median":17.666414,"eighty":26.885017,"marketCap":129456333845.32},{"date":"2024-11-15","current":25.402919,"twenty":10.044628,"median":17.666414,"eighty":26.404422,"marketCap":121101937530.68},{"date":"2024-11-22","current":25.92038,"twenty":10.044628,"median":17.666414,"eighty":25.927346,"marketCap":122518864801.22},{"date":"2024-11-29","current":25.619919,"twenty":10.044628,"median":17.666414,"eighty":25.699083,"marketCap":121788536423.67},{"date":"2024-12-06","current":25.644957,"twenty":10.044628,"median":17.666414,"eighty":25.611269,"marketCap":122139495847.16},{"date":"2024-12-13","current":24.807559,"twenty":10.044628,"median":17.666414,"eighty":25.528111,"marketCap":117246552266.62},{"date":"2024-12-20","current":25.394572,"twenty":10.044628,"median":17.666414,"eighty":25.504351,"marketCap":118799775303.16},{"date":"2024-12-27","current":25.950983,"twenty":10.044628,"median":17.666414,"eighty":25.504351,"marketCap":121782054794.83},{"date":"2025-01-03","current":25.836919,"twenty":10.044628,"median":17.666414,"eighty":25.504351,"marketCap":119394068299.66},{"date":"2025-01-10","current":26.476134,"twenty":10.043718,"median":17.662753,"eighty":25.478661,"marketCap":122813940759.73},{"date":"2025-01-17","current":27.190583,"twenty":10.043718,"median":17.662753,"eighty":25.478661,"marketCap":126128028900.56},{"date":"2025-01-24","current":27.736112,"twenty":10.043718,"median":17.662753,"eighty":25.478661,"marketCap":130118603784.49},{"date":"2025-01-31","current":22.679241,"twenty":10.043718,"median":17.662753,"eighty":25.458421,"marketCap":135796476672.57},{"date":"2025-02-07","current":22.453317,"twenty":10.043718,"median":17.662753,"eighty":25.395685,"marketCap":133815994648.27},{"date":"2025-02-14","current":22.527177,"twenty":10.043718,"median":17.662753,"eighty":25.302609,"marketCap":135139535422.45},{"date":"2025-02-21","current":23.475533,"twenty":10.043718,"median":17.662753,"eighty":25.274251,"marketCap":136588490535.79},{"date":"2025-02-28","current":23.529645,"twenty":10.043718,"median":17.662753,"eighty":25.156716,"marketCap":136134051560.87},{"date":"2025-03-07","current":24.715596,"twenty":10.042807,"median":17.659092,"eighty":25.048936,"marketCap":148818188841.24},{"date":"2025-03-14","current":23.949012,"twenty":10.042807,"median":17.659092,"eighty":24.864048,"marketCap":144656712656.17},{"date":"2025-03-21","current":23.863334,"twenty":10.042807,"median":17.659092,"eighty":24.801725,"marketCap":143967164905.6},{"date":"2025-03-28","current":22.763528,"twenty":10.042807,"median":17.659092,"eighty":24.715596,"marketCap":136620485714.59},{"date":"2025-04-04","current":21.134417,"twenty":10.042807,"median":17.659092,"eighty":24.626125,"marketCap":130072347841.49},{"date":"2025-04-11","current":19.729859,"twenty":10.043718,"median":17.662753,"eighty":24.453364,"marketCap":122690991838.72},{"date":"2025-04-17","current":19.969823,"twenty":10.043718,"median":17.662753,"eighty":24.305248,"marketCap":126259056108.71},{"date":"2025-04-25","current":17.94759,"twenty":10.042807,"median":17.659092,"eighty":24.198495,"marketCap":128365926735.55}],"updateTime":1745728657838}}}